Jager-van Dijk is new Arletta Pharma Solutions CEO 

Brian Attwood | October 13, 2026 | Appointment | |  FDA, Female Sexual Disorders, Genito-Urinary system, HRT, Obstetrics & Gynaecology, specialty pharmaceuticals, women’s health 

Netherlands-based clinical-stage biopharmaceutical company developing innovative therapies for women with Female Sexual Disorders (FSD), Arletta Pharma Solutions has appointed Jeannette Jager-van Dijk as Chief Executive Officer. The global pharmaceutical executive has more than three decades of leadership experience in women’s health, vaccines and specialty pharmaceuticals, including U.S.-based responsibility for the development, registration and commercialization of women’s health products.

Arletta recently received written feedback from the U.S. Food and Drug Administration (FDA) on the proposed design of MONARCH, its planned U.S. Phase 2 study of Lybrido, the Arletta’s lead investigational on-demand, dual-action therapy for women with Female Sexual Interest/Arousal Disorder (FSIAD) and Hypoactive Sexual Desire Disorder (HSDD). The Agency supported core elements of the proposed study design and provided guidance relevant to the potential future development pathway for Lybrido™.